Oncology  

Publication Now Available from the HCC Experts Round Table (Americas & Europe)

Prof. Dr Peter R. Galle

Prof. Dr Peter R. Galle
Publication Date

Sep 2021

info Summary and next episodes download Downloadable resources

This peer-reviewed article from interdisciplinary experts describes the impact of the IMbrave150 trial on treating advanced hepatocellular carcinoma.

 

The HCC Experts Round Table (Americas & Europe) brought together international experts in hepatocellular carcinoma, from fields including oncology, hepatology, radiology, patient advocacy, and health economics. The HCC Experts Round Table has recently published their assessment of the impact of the IMbrave150 trial on standards of care for advanced first-line HCC.

Watch the video overview from manuscript senior author Prof. Peter Galle and download your educational slides, summarizing the conclusions of the HCC Experts Round Table in their peer-reviewed publication. This educational content is relevant for all clinical team members involved in the care of advanced HCC.

Kulik L, da Fonseca LG, He AR, Rimola J, Wilson Woods A, Zöllner YF, Galle PR. Potential Impact of IMbrave150 Results in the Evolving Treatment Landscape of Advanced Hepatocellular Carcinoma: A Multidisciplinary Expert Opinion. J Hepatocell Carcinoma. 2020;7:423

This educational programme is supported by an Independent Educational Grant from Roche.

Hello, my name is Peter Galle, from the University Medical Center in Mainz, Germany. Last year, a multidisciplinary team of experts convened to discuss the impact of the IMbrave150 trial, assessing the combination of atezolizumab and bevacizumab in hepatocellular carcinoma.

This resulted in a position paper, where we discuss the important aspects of the trial with respect to efficacy, safety, and the impact on scheduling of systemic therapy in hepatocellular carcinoma.

We are now at a situation where we have seen a timely update of the data from 2020, which appeared at the ASCO GI meeting in January 2021 in San Francisco. It was good to see that the improvement of overall survival (OS) was not only confirmed, but now it was actually given in absolute numbers: we see a six-month improvement in overall survival comparing atezo + bev versus sorafenib.

This has resulted in the meantime in the approval of this combination in more than 160 countries worldwide, for the benefit of our patients. Thank you for your interest.

Programme summary
Watch the video now
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from Roche
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Roche
I agree that this educational programme:

Was valuable to me

1/4

Other programmes of interest

conference-update Conference update
Oncology 
Highlights from ESMO 2026

Experts join us at ESMO 2026 to share their insights on new data on GI, liver, lung, breast and GU cancers

Experts
Dr Elizabeth Smyth, Dr Yelena Janjigian, Assoc. Prof. Gerald Prager, Prof. Hong Jae Chon, Assoc. Prof. Lorenza Rimassa, Dr Tom Newsom-Davis, Dr Louise Lim, Dr Komal Jhaveri, Dr Roberto Iacovelli
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
MET crusaders ESDO Global Liver Institute
DiCE
  • download Downloadable
    Resources
  • clock 9 MIN
  • calendar Oct 2026
  • Non-accredited Independent Medical Education
COR2ED GI NURSES CONNECT PRECISION ONCOLOGY CONNECT GU NURSES CONNECT GI CONNECT
podcast Video podcast
Oncology 
Metastatic TNBC cannot wait

Optimising 1st line TROP2 ADC decisions in metastatic triple-negative breast cancer

Experts
Prof. Giuseppe Curigliano, Prof. Javier Cortés
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Oct 2026
  • Non-accredited Independent Medical Education
BREAST CANCER CONNECT
Educational programme supported by an Independent Educational Grant from AstraZeneca.
Explore all programmes